newsfilter
← Earnings
Earnings Releases·

C4 Therapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue declined to $8.5 million from $11.2 million in the prior year period due to the conclusion of Merck research activities, while net loss improved to $21.8 million from $32.2 million.
  • Cash and marketable securities stood at $274.7 million as of September 30, 2026, with management confirming this position funds operations through the end of 2028.
  • The Phase 2 MOMENTUM trial is on track to complete enrollment in Q1 2027 with initial ORR data expected in H2 2027, while the Phase 1b cemsidomide/elranatamab trial advanced to expansion cohorts following safety confirmation.
  • The company aims to deliver at least one development candidate to a collaboration partner by year-end 2026 and plans to initiate two additional Phase 1b combination trials in the first half of 2027.
Company
C4 THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology